Key result
Lixisenatide reduced the infarct-size to area at risk ratio by 36% compared to placebo in isolated rat hearts subjected to acute ischemia-reperfusion.
Why the study?
Does lixisenatide reduce infarct size and improve cardiac function in rodent models of myocardial ischemia-reperfusion injury?
Population
Rodent models of myocardial ischemia-reperfusion injury
Comparison
Lixisenatide vs Placebo
Design
Preclinical
Follow-up
10 weeks
Authors
Loading...
Hypothesis-generating for lixisenatide cardioprotection; leaves open translation to human ischemia-reperfusion injury.
Does lixisenatide reduce infarct size and improve cardiac function in rodent models of myocardial ischemia-reperfusion injury?
p-value: p=<0.05
Lixisenatide demonstrates cardioprotective effects in rodent models of ischemia-reperfusion injury through GLP-1 receptor-independent mechanisms.
Wohlfart et al. (2013) studied Myocardial ischemia-reperfusion injury. Lixisenatide vs. Placebo was evaluated on Infarct-size to area at risk ratio (p=<0.05). Lixisenatide reduced the infarct-size to area at risk ratio by 36% compared to placebo in isolated rat hearts subjected to acute ischemia-reperfusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: